Oncomed Pharmaceuticals (NASDAQ:OMED) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, February 21st. Analysts expect Oncomed Pharmaceuticals to post earnings of ($0.35) per share for the quarter.
Oncomed Pharmaceuticals (NASDAQ:OMED) opened at $2.06 on Wednesday. The firm has a market capitalization of $77.98, a price-to-earnings ratio of -1.08 and a beta of 2.23. Oncomed Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $10.89.
Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a research note on Wednesday, November 8th. Cantor Fitzgerald set a $6.00 price target on Oncomed Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $5.81.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.